06 July 2021 | News
To add additional development and manufacturing capacity
image credit- shutterstock
FUJIFILM Corporation, based in Japan, has announced a ¥90 Billion Yen (~$850 Million) investment package to accelerate the growth of its core Bio Contract Development and Manufacturing Organization (CDMO) subsidiary, FUJIFILM Diosynth Biotechnologies.
FUJIFILM Corporation is steadily expanding its Bio CDMO business by investing in FUJIFILM Diosynth Biotechnologies’ strength in contract development and manufacturing to increase capacity to meet the market demands for biopharmaceuticals. This announcement brings the total investments made by Fujifilm in FUJIFILM Diosynth Biotechnologies since 2011 to $5.5B (¥600 Billion Yen).
The $850 Million (¥90 Billion Yen) investment will significantly increase FUJIFILM Diosynth Biotechnologies’ manufacturing capacity. The expansions will double cell culture production for recombinant vaccines in the United States.
In the United Kingdom gene therapy production will be increased ten-fold, cell culture capacity will be tripled and microbial fermentation output at the existing 5,000L scale facility will be doubled.
The United Kingdom cell culture expansion will also include cGMP capacity for continuous manufacturing. Process and analytical development capacity will also be strategically added as part of this investment package. The expansions are scheduled to begin operating by late 2023.